Regulatory approval

Published by the Health Service Executive.

The Republic of Ireland's Health Service Executive (HSE) has approved encorafenib in combination with binimetinib for reimbursement as a treatment option for the treatment of adult patients with advanced (unresectable or metastatic) melanoma with a BRAF V600 mutation.

This is written in the approval document as:

Treatment of adult patients with advanced (unresectable or metastatic) melanoma with a BRAF V600 mutation.

Citation

Encorafenib and Binimetinib Therapy, 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 08/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/563-envorafenib-and-binimetinib-therapy.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) BRAF p.V600E Melanoma Binimetinib, Encorafenib
Sensitivity (+) BRAF p.V600K Melanoma Binimetinib, Encorafenib